Healtcare Advanced Therapy Medicinal Products Market

Advanced Therapy Medicinal Products Market - By Product, Diseases, and End User - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026 Advanced Therapy Medicinal Products (ATMPs) are innovative therapies that comprises cell therapy, gene therapy, and tissue engineered products. Cell therapy products include cellular immunotherapies and autologous and allogeneic cells for certain therapeutic indications including adult and embryonic stem cells. Whereas, Human gene therapy refers to products that introduce genetic material into individuals DNA to replace faulty or missing genetic material, thus treating a disease or abnormal medical condition. These are a novel class of medicines that offer potential treatment opportunities for diseases that have currently limited or no therapeutic options such as hemophilia, cystic fibrosis, metabolic disorders, muscular dystrophies, skin burns, Alzheimer, and cancer. Although majority of ATMPs are in an early stage of development, consolidated trial stage and the chances to cure chronic conditions signify that ATMPs may achieve the market sooner than standard treatments. Furthermore, advanced therapy medicinal products are regulated and authorized for marketing by the Food and Drug Administration (FDA) in the U.S. and by European Medicines Agency (EMA) in the Europe. Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1101 Rising incidences of Alzheimer’s is expected to foster the growth of advanced therapy medicinal products market The factors that are contributing the growth of advanced therapy medicinal products market are rising prevalence of Alzheimer’s disease. According to Alzheimer’s disease International in 2017, around 50 million people were estimated to suffer from Alzheimer’s disease across the globe. Furthermore, rising demand for gene therapies used in the treatment of ocular, neurodegenerative diseases, and several cancers accompanied by technological advancements in genetic engineering tool such as RNAi are the factors that are expected to boost the growth of advanced therapy medicinal products market. However, the factors that are hindering the growth of advanced